Vivek Bhaktaram, MD
Interventional Cardiology · Oklahoma City, OKNPI 1760588545
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 354 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,706 and has fallen 54.6% since, to $774 in 2025.
Across 354 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Boehringer Ingelheim$830
- Novo Nordisk$735
- Amgen$714
- Novartis$669
- Merck$607
- plus $4K from 26 others
What the payments were for
- Food & beverage$8,451100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 61 | $1,082 |
| Boehringer Ingelheim | 32 | $830 |
| Novo Nordisk | 20 | $735 |
| Amgen | 40 | $714 |
| Novartis | 36 | $669 |
| Merck | 30 | $607 |
| AstraZeneca | 13 | $605 |
| E.r. Squibb & Sons, L.L.C. | 27 | $532 |
| Esperion Therapeutics, Inc. | 10 | $497 |
| Abiomed | 3 | $345 |
| Amarin Pharma, Inc. | 12 | $227 |
| Pfizer | 14 | $219 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $203 |
| Shockwave Medical, Inc | 1 | $155 |
| Boston Scientific | 4 | $131 |
| Medtronic | 1 | $119 |
| Lexicon Pharmaceuticals, Inc. | 6 | $113 |
| Alnylam Pharmaceuticals Inc. | 4 | $100 |
| Daiichi Sankyo Inc. | 3 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Baxter Healthcare | 2 | $68 |
| Regeneron Healthcare Solutions, Inc. | 4 | $52 |
| Bayer | 3 | $48 |
| Abbott | 2 | $42 |
| Kestra Medical Technology Services, Inc. | 2 | $42 |
| Lilly USA, LLC | 3 | $41 |
| Vifor Pharma, Inc. | 2 | $34 |
| Edwards Lifesciences | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,451 in reported general payments places this provider in the 55th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $149,953 |
| EntrestoSacubitril/Valsartan | 53 | $65,538 |
| Repatha SureclickEvolocumab | 53 | $54,411 |
| JardianceEmpagliflozin | 44 | $50,151 |
| XareltoRivaroxaban | 25 | $34,685 |
| JanuviaSitagliptin Phosphate | 17 | $16,365 |
| BrilintaTicagrelor | 11 | $12,096 |
| Atorvastatin Calcium | 647 | $7,956 |
| Metoprolol Succinate | 516 | $6,864 |
| Ezetimibe | 229 | $6,579 |
| Rosuvastatin Calcium | 360 | $6,267 |
| Fenofibrate | 17 | $3,814 |
| Losartan Potassium | 329 | $3,716 |
| Carvedilol | 176 | $1,975 |
| Amlodipine Besylate | 202 | $1,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $219 | $149,953150 claims |
| NovartisEntresto | $669 | $65,53853 claims |
| Boehringer IngelheimJardiance | $830 | $50,15144 claims |
| Johnson & JohnsonXarelto | $1,082 | $34,68525 claims |
| MerckJanuvia | $607 | $16,36517 claims |
| AstraZenecaBrilinta | $605 | $12,09611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.